A major international study found that giving children at least one dose of rotavirus vaccine reduced their risk of dying from rotavirus-related diarrhea by approximately 75.8%, yet the United States just moved the vaccine from a universal recommendation to an optional choice between families and doctors. The findings, published in the Lancet Child & Adolescent Health, come at a critical moment as vaccine policy shifts in ways that experts worry could leave vulnerable children unprotected.

What Does the New Research Show About Rotavirus Vaccine Effectiveness?

Researchers analyzed data from more than 27,000 children under age 5 across 22 countries who received care for acute gastroenteritis, or severe diarrhea, between 2007 and 2023. The study, called the Multi-National Subpopulations Study to Evaluate Rotavirus Vaccines (MNSSTER-V), found that vaccinated children were nearly 14 times less likely to die from acute gastroenteritis compared with unvaccinated children. Among the 16 countries that reported deaths, researchers documented 25 rotavirus-positive deaths and 183 total diarrhea-related deaths in children seeking hospital or emergency care.

The protection was most dramatic for rotavirus-specific deaths. Children who received at least one rotavirus vaccine dose had a 75.8% lower risk of dying from rotavirus-positive gastroenteritis. However, the vaccine's effect on all-cause diarrhea deaths was smaller, reducing risk by about 20.8%, though this difference was not statistically significant.

Who Was Most at Risk, and Why Does Geography Matter?

The study revealed stark disparities in both vaccination rates and death risk. Twelve of the 16 countries reporting deaths were located in Africa, highlighting how rotavirus remains a leading cause of childhood mortality in low-income regions. Children treated at rural hospitals were nearly twice as likely to have received no rotavirus vaccine doses compared with those in urban settings, with vaccination rates of 10% versus 5.8% respectively.

Among children who died with confirmed rotavirus infection, a larger proportion had received no rehydration therapy and no vaccine doses compared with children who died from other causes of diarrhea. This pattern underscores a critical gap: rotavirus deaths often occur when two preventive measures fail simultaneously,vaccination does not happen, and life-saving rehydration treatment is unavailable.

How to Protect Children From Rotavirus: Key Steps for Families and Healthcare Providers

• Timely Vaccination Schedule: Infants should receive rotavirus vaccine doses on schedule, as younger infants face the highest risk of severe illness and death from rotavirus and acute gastroenteritis. Completing the full vaccine series is critical for maximum protection.
• Access to Rehydration Therapy: Even vaccinated children can contract rotavirus, so families should know that prompt rehydration with oral rehydration solutions or intravenous fluids can prevent death from severe diarrhea, especially in settings where medical care may be delayed.
• Healthcare Provider Counseling: With rotavirus vaccination now classified as a shared decision between families and clinicians rather than a routine recommendation, pharmacists and doctors should actively discuss the vaccine's mortality benefits during well-child visits and immunization appointments.
• Rural and Underserved Community Outreach: Families in rural areas and low-income settings should receive targeted information about rotavirus vaccine availability, as these communities face both lower vaccination rates and higher death risk from diarrheal disease.

Researchers noted that because younger infants generally face the highest risk of dying from rotavirus, on-schedule vaccination in all settings is essential. Higher coverage could also offer indirect protection to children with chronic conditions who face elevated diarrhea mortality risk.

Why Did the US Just Make Rotavirus Vaccination Optional?

The timing of this research is significant because the United States has just undergone a major shift in vaccine policy. An executive order signed this month moves rotavirus vaccination, along with hepatitis A, hepatitis B, meningococcal disease, influenza, and COVID-19 vaccines, from a universal childhood recommendation to a "shared clinical decision-making" category. This means vaccination is no longer a default recommendation for all children but instead requires individual conversations between families and healthcare providers.

The policy change narrows the list of vaccines recommended for all children from 17 to 11 and directs the Department of Health and Human Services to formalize the revised schedule within 90 days. Critics have warned that reclassifying rotavirus vaccination could reduce coverage rates and, by extension, increase hospitalizations and deaths from a virus that still accounts for an estimated 25% of diarrhea deaths in children under age 5 worldwide, despite more than 140 countries including the vaccine in routine immunization programs.

"Rotavirus vaccine effectiveness against severe disease is known to decline in the second year of life in low- and middle-income countries, a pattern not seen in wealthier nations; however, it remains unclear whether protection against death follows the same trajectory," noted Daniel Hungerford and Latif Ndeketa of the University of Liverpool in an accompanying analysis.

Daniel Hungerford, PhD, and Latif Ndeketa, MBBS, PhD, University of Liverpool

Hungerford and Ndeketa argued that closing vaccine protection gaps will require pairing vaccination with birth-dose strategies, injectable alternatives to oral vaccines, and sustained investment in nutrition, sanitation, and health system infrastructure.

What Does This Mean for Pharmacists and Healthcare Providers?

For pharmacists involved in immunization counseling, the MNSSTER-V findings offer concrete, mortality-based evidence to support timely rotavirus vaccination, particularly as US policy moves toward a shared decision-making framework that places more responsibility on point-of-care conversations. Pharmacists in both community and hospital settings may be well positioned to reinforce completion of the full rotavirus series, especially among infants and families in under-resourced or rural settings, where the study found both vaccination gaps and mortality risk were highest.

The shift from universal recommendation to shared decision-making means that healthcare providers will need to actively educate families about rotavirus risk and vaccine benefits rather than relying on routine default administration. The new research provides the evidence base for those conversations, showing that vaccination offers substantial protection against a disease that still kills thousands of children annually in developing countries and remains a significant cause of hospitalization even in wealthy nations.